Abstract:BACKGROUND AND PURPOSE: Hirudin variants are the most powerful thrombin inhibitors discovered to date, with a lower risk of bleeding than heparin. For anticoagulation, the C-termini of hirudin variants bind to the exocite I of thrombin. Anticoagulant effects of gene-recombinant hirudin are weaker than natural hirudin for the reason of lacking tyrosine O-sulfation at C-terminus.EXPERIMENTAL APPROACH: An integrative pharmacological study was carried out using molecular dynamic, molecular biological and in vivo and in vitro experiments to elucidate the anticoagulant effects of protein-engineered hirudins.KEY RESULTS: Molecular dynamic analysis showed that modifications of the C-termini of hirudin variant 1 of Hirudo medicinalis (HV1) and hirudin variant 2 of Hirudinaria manillensis (HM2) changed the binding energy of the C-termini to human thrombin. The study indicated that Asp61 of HM2 that corresponds to sulfated Tyr63 of HV1 is critical for inhibiting thrombin activities. Further, the anticoagulant effects of HV1 and HM2 were improved when the amino acid residues adjacent to Asp61 were mutated to Asp. These improvements were prolongation of the activated partial thromboplastin time, prothrombin time and thrombin time of human blood, and decreased K<sub>i</sub> and IC<sub>50</sub> values. In the in vivo experiments, mutations at C-termini of HV1 and HM2 significantly changed partial thromboplastin time, prothrombin and thrombin time CONCLUSION AND IMPLICATIONS: The study indicated that the anticoagulant effects of gene-engineered HM2 are stronger than gene-engineered HV1 and HM2-E60D-I62D has the strongest effects and could be an antithrombotic with better therapeutic effects.

Structure Study of Recombinant RGD-Hirudin by Vibrational and Circular Dichroism Spectroscopy

1H NMR assignment and secondary structure of recombinant RGD-hirudin.

The NMR Solution Structure of Recombinant RGD-hirudin

Expression, Purification, and Mass Spectrometric Analysis of 15N, 13C-Labeled RGD-hirudin, Expressed in Pichia Pastoris, for NMR Studies.

Structural basis of RGD-hirudin binding to thrombin: Tyr 3 and five C-terminal residues are crucial for inhibiting thrombin activity

[Fermentation, Purification and Identification of Recombinant RGD-Hirudin].

A Novel Hirudin Derivative Characterized with Anti-Platelet Aggregations and Thrombin Inhibition.

Efficient targeted anticoagulant with active RGD motif.

Construction and Expression of Chimeric Antithrombotics with Hirudin and RGD Sequence

Anti-thrombotic Effect of Recombinant RGD-Hirudin in Artery Anastomosis

Prokaryotic Expression of SA-hirudin-RGD Fusion Proteinand Identification of Its Anticoagulant and Anti-platelet Aggregation Function

Advances in the study of structural modifications of hirudin

Structural Characterization and Anticoagulant Activities of a Keratan Sulfate-like Polysaccharide from the Sea Cucumber <i>Holothuria fuscopunctata</i>

Molecular dynamic and pharmacological studies on protein‐engineered hirudin variants of Hirudinaria manillensis and Hirudo medicinalis

Overproduction of 15N-Labeled R-Rgd-hirudin in Pichia Pastoris for NMR Studies

Design, Preparation and in Vitro Bioactivity of Mono-PEGylated Recombinant Hirudin

Computational Design, Functional Analysis and Antigenic Epitope Estimation of a Novel Hybrid of 12 Peptides of Hirudin and Reteplase

Studies on Anticoagulant and Antithrombotic Effects of Recombinant Hirudin-Ⅲ

Molecular cloning of hirudin derivative cDNA gene and expression in mammalian cell

The antithrombotic effect of a novel hirudin derivative after reconstruction of carotid artery in rabbits

Comparison of Linear Vs. Cyclic RGD Pentapeptide Interactions with Integrin Αvβ3 by Molecular Dynamics Simulations